Regal Asian Investments (ASX:RG8) has significantly devalued its holdings in biopharmaceutical company Opthea after the latter flagged insolvency concerns amid the failure of a major clinical trial. https://www.financialstandard.com.au/feed/latest?story=179807984 en-AU Copyright 2026 Financial Standard 5